Science Current Events | Science News |

Combining therapies can improve survival for early-stage breast cancer patients

April 04, 2007

Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen. But a combination of tamoxifen and ovarian suppression—treatment to stop the ovaries from functioning—did not show any additional benefits, according to two randomized clinical trials published in the April 4 Journal of the National Cancer Institute.

Survival rates improve for patients with early-stage breast cancer who receive a single method of treatment—either tamoxifen, ovarian suppression, or chemotherapy. Two international studies by the Adjuvant Breast Cancer Trials Collaborative Group were designed to test whether combining these treatments would provide additional benefits.

Judith Bliss of The Institute of Cancer Research in Sutton, England, and colleagues conducted two randomized controlled phase III clinical trials of 3,854 women with early-stage breast cancer, all of whom were treated with tamoxifen for five years. In the first trial, nearly half of the 2,144 premenopausal women were randomly assigned to receive ovarian suppression, and the other half did not. Some also received chemotherapy. In the second trial, 1,991 patients were randomly assigned to receive chemotherapy, and the other half were not. Some premenopausal women also had ovarian suppression.

The researchers found that chemotherapy treatment resulted in a modest yet sustained improvement in both relapse-free and overall survival. These improvements were especially strong in women younger than 50 years and in premenopausal women who did not receive ovarian suppression.

They also found that neither relapse-free survival nor overall survival was affected by the addition of ovarian suppression. However, the results indicate a possible benefit of ovarian suppression when given along side tamoxifen for a small group of women younger than 40 years who have ER-positive tumors (tumors that need estrogen to grow), especially when they are not receiving chemotherapy. The researchers called for further research into this group of breast cancer patients.

"Relapse-free survival benefits emerged early and were maintained, whereas overall survival benefits did not emerge for at least 5 years, reinforcing the need for long-term follow-up in chemotherapy trials," the authors write. The trials add "to the limited data available on the effects of combining long-term tamoxifen, chemotherapy, and ovarian ablation of suppression."

In an accompanying editorial, Kathleen Pritchard, M.D., of Toronto Sunnybrook Regional Cancer Centre, describes how the trial could have found more interesting results if there had been more data on patients' ER status. "Most of all, however, these studies stress the importance of establishing processes to ensure the availability of archived tumor specimens for all randomized adjuvant trials. The era in which such large important trials should be carried out without the archived correlational tumor samples is over."

Journal of the National Cancer Institute

Related Tamoxifen Current Events and Tamoxifen News Articles

No need to stop antidepressants before plastic surgery, evidence suggests
For patients undergoing plastic surgery procedures, there's no consistent evidence that taking antidepressants increases the risk of bleeding, breast cancer, or other adverse outcomes, concludes a research review in the November issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Study shows association between breastfeeding and reduced risk of aggressive breast cancer
A large international study shows that breastfeeding is associated with a lower risk of developing an aggressive form of breast cancer called hormone-receptor negative.

Multi-gene test enables some breast cancer patients to safely avoid chemotherapy
A major study published in the New England Journal of Medicine is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.

New approach found to tackle breast cancer hormone therapy resistance
University of Manchester researchers funded by Breast Cancer Now have discovered a new explanation as to why women with oestrogen receptor positive (ER+) breast cancer develop resistance to hormone treatment, and a potential new approach to overcome the problem.

Use of tamoxifen by young women is influenced by fertility concerns
The risk of breast cancer recurrence and mortality is decreased by endocrine therapy (ET) such as tamoxifen, but younger patients may decline it or discontinue treatment early if they are concerned about fertility, according to a study published August 24 in the JNCI: Journal of the National Cancer Institute.

Tool boosts accuracy in assessing breast cancer risk
A national risk model that gauges a woman's chance of developing breast cancer has been refined to give a more accurate assessment.

New studies show that 2 classes of inexpensive generic drugs can reduce breast cancer deaths
Two new studies, both published in The Lancet, suggest that two different classes of drugs, aromatase inhibitors (AIs) and bisphosphonates, can each improve survival prospects for postmenopausal women with early breast cancer.

Scientists identify schizophrenia's 'Rosetta Stone' gene
Scientists have identified a critical function of what they believe to be schizophrenia's "Rosetta Stone" gene that could hold the key to decoding the function of all genes involved in the disease.

Life-saving breast cancer drugs going untaken in Appalachia
Nearly a third of breast cancer survivors in Appalachia are not taking the critical, potentially life-saving follow-up treatment - despite having insurance that would pay for it, a troubling new study has found.

Stress hormones could undermine breast cancer therapy
Recently, researchers have discovered that the hormone progesterone, an ingredient in contraceptives and menopausal hormone replacement therapies, might stimulate the growth of breast cancer cells that are resistant to anti-estrogen therapy and chemotherapy.
More Tamoxifen Current Events and Tamoxifen News Articles

Tamoxifen and Breast Cancer (Yale Fastback Series)

Tamoxifen and Breast Cancer (Yale Fastback Series)
by Michael W. DeGregorio (Author), Valerie J. Wiebe (Author)

A discussion of the diagnosis of breast cancer and the risks, benefits and limitations of treatment alternatives, particularly tamoxifen. This edition contains information on developments in the use of tamoxifen, especially in the results of the Breast Cancer Prevention Trial.

The Whole-Food Guide for Breast Cancer Survivors: A Nutritional Approach to Preventing Recurrence (The New Harbinger Whole-Body Healing Series)

The Whole-Food Guide for Breast Cancer Survivors: A Nutritional Approach to Preventing Recurrence (The New Harbinger Whole-Body Healing Series)
by Edward Bauman MEd PhD (Author), Helayne Waldman MS EdD (Author), Donald I. Abrams MD (Foreword)

If you’re a breast cancer survivor, chances are you have renewed your commitment to maintaining your good health and taking care of your body. As one of the best preventative measures known to doctors and nutritionists today, a robust, cancer-fighting diet is vital to your personal plan for breast cancer prevention.The Whole-Food Guide for Breast Cancer Survivors is an essential guide for every woman seeking to understand the effect of nutritional deficiencies and environmental factors on her overall health and wellness. Based on Edward Bauman’s groundbreaking Eating for Health model, this highly comprehensive, practical approach can help you reduce the chance of breast cancer recurrence; rebuild your immune system; and enjoy a stronger, healthier body.Reduce the chance of breast...

Tamoxifen: Pioneering Medicine in Breast Cancer (Milestones in Drug Therapy)

Tamoxifen: Pioneering Medicine in Breast Cancer (Milestones in Drug Therapy)
by Springer

Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the...

Tamoxifen: Beyond the Antiestrogen

Tamoxifen: Beyond the Antiestrogen
by Birkhäuser

Tamoxifen has persisted as a widely accepted and administered drug for almost 25 years. Following the many scientific papers and books on the subject, it has remained a very intriguing substance. This, perhaps, is the reason for another monograph on Tamoxifen. It is regrettably true that overviews, even when up to date after exhaustive research - the shibboleth of our cultures -, rapidly lose relevance with the passage of time. Scientists can sometimes be pictured as deep sea divers, who plunge into the unknown in search of a hitherto unknown world. Their descent is exciting, but eventually they must come up for air and integrate their experiences with others who also had to resurface. This book intends to collect and, where possible, to collate recent, but sometimes seemingly unrelated...

Tamoxifen: New Hope in the Fight Against Breast Cancer

Tamoxifen: New Hope in the Fight Against Breast Cancer
by John F. Kessler (Author), Greg A. Annussek (Author)

On the market in the United States since 1978, tamoxifen is the most widely prescribed anti-cancer drug in the world. Recently, this powerful cancer fighter has been found to prevent breast cancer, and its use as a breast cancer preventive has been approved by the FDA. For women at high risk of breast cancer, tamoxifen provides a new option for prevention of this disease. Now, in this comprehensive, accessible guide, a medical doctor provides answers to the critical questions every woman should ask before considering preventive therapy or cancer treatment with tamoxifen.Should I consider myself at high risk of breast cancer?
Do the risks of breast cancer outweight the risks of taking tamoxifen?
How does tamoxifen compare with other prevention therapies?
What are the side effects...

The Wisdom of Menopause (Revised Edition): Creating Physical and Emotional Health During the Change

The Wisdom of Menopause (Revised Edition): Creating Physical and Emotional Health During the Change
by Christiane Northrup M.D. (Author)

Dr. Christiane Northrup’s #1 New York Times bestseller The Wisdom of Menopause has inspired more than a million women with a dramatically new vision of midlife—and will continue to do so for generations to come. As Dr. Northrup has championed, the “change” is not simply a collection of physical symptoms to be “fixed,” but a mind-body revolution that brings the greatest opportunity for growth since adolescence. The choices a woman makes now—from the quality of her relationships to the quality of her diet—have the power to secure vibrant health and well-being for the rest of her life.

Now completely revised, this groundbreaking classic draws on the current research and medical advances in women’s health, and includes
• a new section on sex after 50—and...

Dr. Susan Love's Breast Book (A Merloyd Lawrence Book)

Dr. Susan Love's Breast Book (A Merloyd Lawrence Book)
by Susan M. Love MD (Author), Karen Lindsey (Contributor), Elizabeth Love (Contributor)

For a woman faced with a diagnosis of breast cancer, the information available today is vast, uneven, and confusing. For more than two decades, readers have relied on Dr. Susan Love's Breast Book to guide them through this frightening thicket of research and opinion to find the best possible options for their particular situations. This sixth edition explains exciting advances in targeted treatments, hormonal therapies, safer chemotherapy, and immunologic approaches as well as new forms of surgery and radiation. There is extensive guidance for the increasing number of women living for years with metastatic breast cancer. With Dr. Love's warm support, readers can sort the facts from the fads, ask the right questions, and recognize when a second opinion might be wise.

What Your Doctor May Not Tell You About Premenopause: Balance Your Hormones and Your Life From Thirty to Fifty

What Your Doctor May Not Tell You About Premenopause: Balance Your Hormones and Your Life From Thirty to Fifty
by John R. Lee (Author), Jesse Hanley (Author), Virginia Hopkins (Author)

An expert in women's health offers a safe, proven, effective hormone balance program for the more than 50 million women suffering from premenopause syndrome

The New Generation Breast Cancer Book: How to Navigate Your Diagnosis and Treatment Options-and Remain Optimistic-in an Age of Information Overload

The New Generation Breast Cancer Book: How to Navigate Your Diagnosis and Treatment Options-and Remain Optimistic-in an Age of Information Overload
by Dr. Elisa Port (Author)

From an expert in the field comes the definitive guide to managing breast cancer in the information age—a comprehensive resource for diagnosis, treatment, and peace of mind.
The breast cancer cure rate is at an all-time high, and so is the information, to say nothing of the misinformation, available to patients and their families. Online searches can lead to unreliable sources, leaving even the most resilient patient feeling uneasy and uncertain about her diagnosis, treatment options, doctors, side effects, and recovery. Adding to a patient’s anxiety is input from well-meaning friends and family, with stories, worries, and opinions to share, sometimes without knowing the details of her particular case, when in reality breast cancer treatment has gone well beyond a “one...

Curing Cancer with Carrots

Curing Cancer with Carrots
by Ann Cameron (Author), Geoff Ward (Editor), Anne Marie Skye (Editor)

In 2013, Ann Cameron cured Stage 4 colon cancer without chemotherapy or radiation, by drinking carrot juice. Since then, others with a variety of cancers have reported similar successes. Cameron wanted to find out why such an apparently simple cancer cure--just carrots--works. Based on her extensive reading in scientific journals focused on nutrition and cancer, her ground-breaking book describes the details of the carrot treatment and the scientific evidence for its power. In this book, she shares little-known research that is revolutionizing scientific thinking about cancer and how to treat it. The research comes from the exciting new field of epigenetics--the study of how chemical switching mechanisms in our bodies change the expression of our genes. Our environment, the foods we...

© 2015